High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases
Clinical trial NCT05379803 · RECRUITING
Trial details
- NCT number
- NCT05379803
- Sponsor
- Hunan Province Tumor Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-01
- Primary completion
- 2024-12-31
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.